Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (ISRG) closed at $476.16 in the latest trading session, marking a +1.34% move from the prior day.

Intuitive Surgical, Inc. (ISRG) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Investors have been looking at robotics companies for several decades. But artificial intelligence (AI) is taking robotics beyond basic automation by bringing more precision, flexibility, and adaptability into the sector.

3 Robotics Stocks at the Heart of the Robotics Revolution

The use of robotics in surgery is on the rise. The market was valued at $800 million in 2015, and has since risen to over $3 billion.

A Rise In Surgical Robotics Could Send These 2 Healthcare Stocks Soaring

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know

Intuitive Surgical expands Ion into Australia and Korea after 52% procedure growth, testing Asia-Pacific adoption despite budget headwinds.

ISRG's International Push for Ion: Strategic Bet or Overstretch?

Investing styles tend to evolve as people age. Seniors who are already retired often look for steady, reliable, dividend-paying companies.

If You're in Your 30s, Consider Buying These 2 Healthcare Stocks

Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.

ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue?

Intuitive Surgical's da Vinci system is driving strong global growth, with 17% YoY procedure growth and expanding adoption across hospitals and specialties. Recurring revenue streams from system sales, procedures, and services support robust financials, including 21% YoY revenue growth and 68% gross margins. The company's expanding installed base and accelerating procedure growth position it for continued earnings stability and long-term shareholder returns.

Intuitive Surgical Has More Room To Grow

Intuitive Surgical's Q2 revenues and procedure gains look good, but tariffs, cost inflation, and margin pressure spur a post-earnings selloff.

ISRG's Post-Earnings Slide: Margin Worries Overshadow Growth Story

Investing in stocks is both accessible to the general public and likely to yield strong returns over the long term. That's what makes it one of the best ways to increase your wealth.

2 Surefire Stocks to Invest $1,000 in for the Long Haul

Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock

Intuitive Surgical's Ion platform posted 52% procedure growth in Q2, but rising system utilization and workflow efficiency now drive its profitability focus.

ISRG's Ion Platform Sees Uptick in Utilization, Eyes Efficiency

If you're a growth-oriented investor like me, you've probably seen your portfolio experience its fair share of ups and downs the last few years. While the market has rebounded to new heights and many growth businesses have recovered spectacularly, results have varied by individual stock.

The Best Growth Stocks I'd Buy Right Now

Investing in stocks for the long term can help you build a profitable portfolio that enables you to meet your personal financial goals. Not every stock will be a winner, and no investor is perfect.

2 Monster Stocks to Hold for the Next 5 Years

Cathie Wood is built for rallying markets. The co-founder, CEO, and chief investment officer of Ark Invest is crushing the market this year, proving that she can catch 2020 in a bottle again.

Cathie Wood Goes Shopping: 3 Stocks She Just Bought

Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know

Intuitive Surgical's Q2 gross margin declines to 67.9% as product mix shifts, new facility costs and tariffs weigh on profitability.

ISRG's Gross Margin Falls on Product Transition and Trade Pressures

Intuitive Surgical (ISRG 1.46%) is one of the best success stories you'll find in the healthcare sector. The company has helped patients worldwide as a pioneer in robotic-assisted surgery, and its business success has driven the stock to returns of over 25,000% since its initial public offering (IPO) in 2000.

Where Will Intuitive Surgical Be in 5 Years?

ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.

Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?

Live Updates Live Coverage Has Ended Conference Call Has Begun 4:40 pm by Eric Bleeker ISRG is set to host its earnings call on Tuesday, July 22 at 1:30 pm PDT. You can join the live webcast by registering here. What&#039;s Depressing Shares? 4:25 pm by Eric Bleeker Shares are down 3.5%. This earnings season has seen plenty of stocks posting strong earnings beats fall in after-hours trading. We can now add Intuitive Surgical to that list. The likely reason for the fall is the company projecting da Vince procedure growth at 15.5% to 17% in 2024, compared to 17% growth last quarter. Margin guidance may also be weighing on the stock in after-hours trading. More Details on Q2 4:22 pm by Eric Bleeker ISRG | Intuitive Surgical Q2&#8217;25 Earnings Highlights: Adj. EPS: $2.19 ; UP +23% YoY Revenue: $2.44B []; UP +21% YoY Adj. Gross Margin: 66.5% []; DOWN -260 bps YoY Net Income: $658M []; UP +25% YoY Outlook: The Company expects worldwide da Vinci procedure growth of approximately 15.5% to 17% in 2025, compared to 17% in 2024. Non-GAAP gross profit margin is expected to be within a range of 66% and 67% of revenue in 2025, reflecting an estimated impact from tariffs of 1.0% of revenue, plus or minus 20 basis points. Non-GAAP operating expense growth is projected at 10% to 14% in 2025, compared to 10% in 2024. Q2 Segment Performance: Instruments and Accessories Revenue: $1.47B []; UP +18% YoY Systems Revenue: $575M []; UP +28% YoY Services Revenue: $391M []; UP +23% YoY Other Key Q2 Metrics: Adj. Operating Income: $946.6M []; UP +25% YoY Adj. Operating Expenses: $874.5M []; UP +9% YoY R&amp;D Expenses: $313.3M []; UP +12% YoY Effective Tax Rate: 20.2% (vs. 18.8% YoY) Cash, Cash Equivalents, and Investments: $9.53B; UP +5% YoY CEO Commentary: Dave Rosa: &#8220;We’re pleased with our solid performance this quarter, highlighted by continued customer adoption of our newer and existing platforms, including da Vinci 5. We are committed to advancing care, and helping our customers provide better patient outcomes, better patient and care team experiences, broadening access to care and decreasing the total cost of care.&#8221; Strategic Updates: In July 2025, the Company obtained European certification for its da Vinci 5 surgical system for adult and pediatric use in minimally invasive endoscopic procedures. In June 2025, the Company obtained regulatory clearance in Japan for the da Vinci 5 surgical system for use in all surgical specialties and procedures indicated for da Vinci Xi, except for cardiac indications. Currently Down 3.5% 4:20 pm by Eric Bleeker As of 4:20 p.m. ET shares are down about 3.5%. We&#8217;re still going through Intuitive Surgical&#8217;s filing and will continue updating this live blog. Growth Rates 4:13 pm by Eric Bleeker Here&#8217;s how last quarter compares to a year ago: Metric Q2 25 Q2 24 YoY Change Revenue $2.44B $2.01B 21.40% Gross Profit $1.62B $1.37B 17.86% Operating Income $743.00M $567.30M 30.97% Net Income $658.00M $526.90M 24.88% Cash And Equivalents $9.53B $3.04B 213.91% Total Assets $20.16B $16.65B 21.10% Total Liabilities $2.21B $1.85B 19.25% Shareholders Equity $17.95B $14.71B 22.06% More on Earnings... 4:12 pm by Eric Bleeker Intuitive Surgical Inc. reported strong financial results for Q2 2025, with revenue reaching $2.44 billion, a 21% increase compared to $2.01 billion in Q2 2024. The company saw significant growth in its da Vinci surgical system placements, with 395 systems placed, including 180 of the newer da Vinci 5 systems. Non-GAAP net income was $798 million, or $2.19 per diluted share, surpassing the estimated EPS of $1.93. The company also achieved regulatory milestones, obtaining European certification for its da Vinci 5 system and regulatory clearance in Japan. CEO Dave Rosa highlighted the company&#8217;s commitment to advancing care and improving patient outcomes. The company ended the quarter with $9.53 billion in cash and investments, reflecting robust operational cash flow. The Numbers 4:10 pm by Eric Bleeker Revenue: $2.44 billion (consensus estimates of $2.35 billion) EPS (Normalized): $2.19 (consensus estimates of $1.93) Earnings Are Out 4:09 pm by Eric Bleeker Earnings are out and Intuitive Surgical shares briefly spiked before falling 3%. We&#8217;re digging into the numbers and will continue providing live updates that appear automatically if you stay on this page. A Little Bit of Selling Before the Close 3:57 pm by Eric Bleeker There&#8217;s been some selling pressure on Intuitive Surgical shares before the close. Right now the stock is down about .9%. Earnings should be releasing shortly after the 4 p.m. close. How Intuitive Surgical stock performed after past earnings 3:30 pm ISRG shares have shown consistent upside momentum post-earnings, especially following double-digit EPS beats. Quarter EPS Surprise 1-Day Move 7-Day Move 14-Day Move Q1 2025 +4.41% +1.2% +2.8% +4.5% Q4 2024 +23.73% +8.7% +10.4% +12.2% Q3 2024 +12.25% +2.9% +3.6% +5.1% Q2 2024 +15.51% +4.1% +6.9% +9.3% Intuitive Surgical (NASDAQ: ISRG) reports earnings this evening, and the bar is high. The robotic surgery pioneer has already logged four straight beats, and Wall Street sees another solid quarter with strong procedure growth, da Vinci system placements, and resilient hospital capex. What to Expect When ISRG Reports Q2 2025 Results Wall Street consensus for the 2nd quarter: Revenue: $2.35 billion EPS (Normalized): $1.93 Full-year expectations: FY 2025 Revenue: $9.66 billion FY 2025 EPS: $7.83 That reflects 15.6% revenue growth and 6.7% EPS growth for the year, with gross margin stability expected despite FX and pricing pressures Key Areas to Watch When ISRG Reports Tonight Here are the key themes investors will be watching: 1.Procedure Growth Resilience ISRG reported Q1 procedure volume +16%, with strength in general surgery and benign gynecology. Investors expect continued momentum, especially in U.S. and Korea. 2. Installed Base &amp; Placements da Vinci system placements were strong in Q1. Management commentary on Q2 placements and outlook for new hospitals adopting multi-port vs. single-port will be key. 3. Next-Gen System &amp; AI Integration CEO Guthart highlighted investments in advanced vision, real-time analytics, and AI decision-support. Analysts may push for clarity on commercial timelines. 4. Capital Spending Environment With macro uncertainty and deferral trends seen in some capex-heavy names, ISRG’s visibility into second-half U.S. and international demand will be crucial. 5. International Penetration Watch for color on uptake in China and EMEA, where currency headwinds and regulatory pacing remain factors. The post Live: Intuitive Surgical (Nasdaq: ISRG) Earnings Preview Coverage appeared first on 24/7 Wall St..

Live: Intuitive Surgical (Nasdaq: ISRG) Earnings Preview Coverage

Real-time stock quote and overview for ISRG